Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
NCT00016341
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the absorption of estrogen. It is not yet known whether chemotherapy is more effective than hormone therapy in treating endometrial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with that... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/10/2013
Locations: Brookview Research, Inc., Nashville, Tennessee
Conditions: Endometrial Cancer
Register for Updates
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
NCT00054067
Terminated
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of radiation therapy combined with chemotherapy, with or without surgery, is more effective in treating early cancer of the cervix. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery followed by different regimens of radiation therapy and chemotherapy wit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Southeast Gynecologic Oncology Associates, Knoxville, Tennessee +1 locations
Conditions: Cervical Cancer
Register for Updates
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT00680758
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of cisplatin, paclitaxel, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2013
Locations: Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee +3 locations
Conditions: Breast Cancer
Register for Updates
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00002642
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to kill tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy using cisplatin and etoposide, radiation therapy, and surgery, with adjuvant therapy using cisplatin and etoposide, in treating patients who have stage III non-small cell lung... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Vanderbilt Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00639769
Completed
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: To determine if CPT-11 given together with cisplatin is effective in treating recurrent or metastatic head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2012
Locations: Erlanger Health System, Chattanooga, Tennessee +6 locations
Conditions: Head and Neck Cancer
Register for Updates
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00020696
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/07/2012
Locations: Brookview Research, Inc., Nashville, Tennessee
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00077883
Completed
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: The Sarah Cannon Cancer Center, Nashville, Tennessee
Conditions: Non-small Cell Lung Cancer
Register for Updates
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
NCT00116896
Completed
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2009
Locations: Vanderbilt Universtiy Medical Center, Nashville, Tennessee
Conditions: Advanced Solid Tumors
Register for Updates